Summary N-Benzyladriamycin-14-valerate (AD198) is a novel lipophilic anthracycline with greater in vivo antitumour activity than doxorubicin (DOX) in experimental model systems. Using sensitive and progressively DOX-resistant L1210 mouse leukaemia and B16-BL6 mouse melanoma lines, we have determined the cellular pharmacokinetics and cytotoxic response in vitro and in vivo of AD 198. In the L1210 leukaemia model following 3 h drug exposure in vitro, the IC,0 for AD 198 was approximately 0.35 1sgm1' for the sensitive and 10-fold DOX resistant cells and 1.0 gsg ml-' for the 40-fold DOX resistant cells. A similar pattern of cross-resistance to AD 198 was also observed with the B16-BL6 melanoma, with an IC50 for AD198 with the sensitive and 10-fold DOX-resistant cells being similar, and about 2-fold higher with the 40-fold resistant cells. In the L1210 leukaemia model, cellular pharmacokinetics of AD198 revealed the following: (a) accumulation of AD198 was concentration but not time dependent, and cellular drug levels in the sensitive and resistant sublines were similar when treated with equimolar concentrations; (b) retention of AD198 was 60% of the initial drug uptake and, in cells treated with the IC,u of AD198, cellular levels in the 40-fold DOX-resistant line were, as expected, 2-fold higher than in sensitive or 10-fold DOX-resistant cells; (c) in vitro biotransformation of AD 198 in the sensitive and resistant sublines was comparable. Studies in vivo with i.p. L1210 leukaemia (disseminating) and B16-BL6 melanoma (non-disseminating) tumour models evaluating therapeutic efficacy of DOX vs AD198 in mice implanted with tumour i.p. on day 0 and treated i.p. on days 1-4 indicated: (a) DOX at 3 mg kg-' administered once daily on days 1 -4 resulted in a 55% ILS and 104% ILS with parent-sensitive B16-BL6 melanoma and L1210 leukaemia models respectively; however, similar doses of DOX in the resistant sublines were ineffective, with survival similar to the untreated control; (b) AD198 at 10-12.5mg kg-' day for 4 days was extremely effective in the sensitive L1210 (189% ILS), and similar to DOX (61% ILS) in the sensitive B16-BL6; (c) AD 198 (10-12.5 mg kg-') was ineffective (survival similar to untreated control) in the 10-and 40-fold DOX-resistant L1210 leukaemia and 40-fold DOX resistant B16-BL6 melanoma, but produced a 76% ILS in the 10-fold DOX resistant B16-BL6 melanoma. Results from this study demonstrate: (a) in vitro AD 198 is capable of circumventing resistance to DOX in the cell lines studied; (b) unlike DOX, cellular levels of AD198 are independent of the level of resistance; (c) in vitro cellular pharmacokinetics and cytotoxicity studies of novel anthracyclines by themselves may be of limited value in characterising therapeutic efficacy of agents for the treatment of DOX resistant tumours in vivo; and (d) the characteristics of disseminating vs non-disseminating tumour model systems can influence outcome of in vivo studies focused on circumvention of cellular resistance.
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The potent antitumour antibiotic doxorubicin (DOX) continues in wide use in the chemotherapeutic management of a broad spectrum of human malignancies (Blum & Carter, 1974; Young et al., 1981) . However, the effectiveness of this agent is often limited by tumour cell resistance which may be of an 'intrinsic' or 'acquired' nature. Over the past several years, the search for more efficacious analogues of DOX has resulted in the development of a number of naturally occurring as well as semisynthetic anthracycline analogues. Based on their differences from DOX in mechanistic and pharmacokinetic properties, some of these products appear to offer a possible advantage for use against resistant tumours (Muggia et al., 1982; Israel et al., 1987a (Skovsgaard, 1978; Inaba et al., 1979) . This alteration in drug accumulation, now recognised to be associated with the multidrug resistant (MDR) phenotype, is suggested to result from a P-glycoprotein-mediated active efflux of cellular drug. This plasma membrane protein (M, 160,000-180,000) has also been demonstrated to serve as a marker in cells resistant to DOX and other drugs of diverse structure and mechanistic action (Gerlach et al., 1986b) . Certain calcium modifiers, i.e. calcium antagonists and calmodulin inhibitors, are now known to be capable of modulating the resistant phenotype, possibly by enhancing cellular DOX levels (Tsuruo et al., 1982; Ganapathi & Grabowski, 1983) .
While cellular pharmacology studies with DOX have provided some basis to demonstrate the relationship of intracellular drug levels to cytotoxicity, it has also been noted that the magnitude of the reduction of cellular drug accumulation in resistant cells frequently does not correlate with the expression of resistance Ganapathi et al., 1986; Louie et al., 1986 ). An important finding which appears not to substantiate reduced anthracycline accumulation as the major determinant of cytotoxicity is that certain lipophilic anthracyclines are accumulated to a similar extent in sensitive and resistant murine P388 leukaemia cells (Ganapathi et al., 1984 (Ganapathi et al., , 1985 , and yet show no significant capacity to circumvent DOX resistance to this tumour in vivo (Johnson et al., 1978; Chandrasekaran et al., 1987) . Although incompletely understood at the present time, the limited in vivo activity of these lipophilic anthracyclines may possibly relate to the artificially high levels of DOX resistance (100-fold or greater) conferred upon these model systems.
Recently, N-benzyladriamycin-14-valerate (AD 198) has been described as a newer lipophilic anthracycline analogue therapeutically superior to DOX in murine tumour systems and with novel biochemical and pharmacological properties growth-inhibitory and anticlonogenic activity against biochemically different resistant sublines as compared to the parent sensitive cell lines, suggesting that this compound may possess an ability to circumvent resistance even due to differing mechanisms (Maniar et al., 1988; Sweatman et al., 1988) . Based on these findings, the present study with AD 198 was undertaken to characterise the relationship between cellular drug levels and antitumour activity in vitro and in vivo utilising two recently described progressively DOX-resistant (5-40-fold) murine tumours, namely L1210 leukaemia and B16-BL6 melanoma (Ganapathi et al., 1987 .
Materials and methods
Drug materials AD 198 and N-benzyladriamycin (AD 288) were prepared as previously described (Israel & Seshadri, 1986 
Tumour cell lines
The sensitive and progressively DOX-resistant sublines of murine L1210 leukaemia and B16-BL6 mouse melanoma have been previously described (Ganapathi et al., 1987 . Briefly, these sublines were developed by adapting cells to grow continuously in the presence of 0.05jig ml-' and 0.25 jg ml-' DOX and are identified as L1210/DOXO.05, L1210/DOXO.25, B16-BL6/ DOXO.05 and B16-BL6/DOXO.25. Based on in vitro cytotoxicity studies using a soft agar colony formation assay, the sublines selected in 0.05 jig ml-' DOX and 0.25 jig ml-' DOX were 10-fold and 40-fold DOX resistant, respectively, compared to the corresponding parent sensitive cells (Li210/ S or B16-BL6/S).
Parent sensitive (L1210/S) and DOX-resistant sublines (L1210/DOXO.05 and L1210/DOXO.25) of L1210 leukaemia were maintained in vitro as suspension cultures using RPMI 1640 medium, supplemented with 25 mM HEPES buffer, 2 mM L-glutamine, 10% fetal bovine serum (FBS), and 10 jiM 2-mercaptoethanol. The doubling time in vitro of the L1210 sensitive and DOX-resistant sublines was 10.7 ± 0.1 h . The parent-sensitive (B16-BL6/S) and DOX-resistant sublines (B16-BL6/DOXO.05 and B16-BL6/DOXO.25) of B16-BL6 melanoma were maintained in vitro as monolayer cultures using Eagle's minimum essential medium with Hank's salts, supplemented with non-essential amino acids, sodium pyruvate, vitamins, 2 mM L-glutamine and 5% FBS. Cells were subcultured weekly using 0.25% trypsin, 0.02% EDTA. The doubling time in vitro of the sensitive and progressively DOX-resistant sublines of B16-BL6 melanoma was approximately 16-18 h (Ganapathi et al., 1987 . All in vitro cultures were maintained at 37% in a humidified 5% CO2 plus 95% air atmosphere. Media and supplements were obtained from M.A. Bioproducts, (Walkersville, MD, USA) and FBS was from Hyclone Laboratories (Logan, UT, USA).
AD 198 and AD 288 in vitro cytotoxicity Cytotoxicity studies were carried out using a soft agar colony-forming assay with 10% FBS were treated with 0.25 jig ml-', 0.5 jig ml-' and 1.0 jLg ml-' AD 198 at 37°C in a humidified 5% CO2 plus 95% air atmosphere. Duplicate aliquots (1 x 106 cells per sample), removed at the end of 1 h of treatment, were centrifuged (100 g) and washed twice with 7 ml of ice-cold 0.85% sodium chloride solution. The cells pellet following the final wash was resuspended in 50% ethanol, 0.3N hydrochloric acid, mixed thoroughly in a vortex mixer and centrifuged (700 g), and the total anthracycline content in the supernatant was determined fluorimetrically in an AmincoBowman spectrophotofluorometer (American Instruments Co., Silver Springs, MD) at excitation and emission wavelengths of 470 nm and 585 nm, respectively (Ganapathi et al., 1984 (Ganapathi et al., , 1985 . Standard curves of AD 198 prepared in 50% ethanol, 0.3N hydrochloric acid were used for computation of total anthracycline content, which was expressed as nmol AD 198-equivalents per 106 cells.
Cellular anthracycline accumulation was also determined by HPLC/flow fluorescence analysis following 3 h drug exposure as part of a detailed study on drug uptake, retention and biotransformation. As above, L1210/S, L1210/ DOXO.05 and L1210/DOXO.25 cells were exposed to AD 198 at their IC50 concentrations (0.5, 0.5, 1.0 jLg ml-', respectively). After 3 h incubation, the cells were harvested and washed twice with ice-cold 0.85% sodium chloride solution, and the resulting cell pellets were sonicated in cold 0.85% sodium chloride solution (2 ml). For analysis, samples, in duplicate, were diluted with Tris buffer (0.05 M, pH 8.5, 3 ml) and subjected to organic extraction (ethyl acetate: 1-propanol, 9:1 by volume, 2 x 8 ml). The two organic extracts for each sample were combined and evaporated to dryness (37°C) under a stream of dry nitrogen gas. Dried samples were stored at -70°C pending analysis. The efficiency of extraction was monitored by reference to standard curves derived from the extraction of known quantities of authentic standards added to sonicates of untreated cells. (Israel & Seshadri, 1986; Israel et al., 1987a Israel et al., , b, 1989 used in these studies were based on the optimal doses for these compounds determined in earlier studies (Israel et al., 1975 (Israel et al., , 1986 (Israel et al., , 1987a Since it is widely accepted that reduced cellular drug uptake and/or retention of anthracyclines is a major mechanism involved in the expression of the MDR phenotype (Inaba et al., 1979; Gerlach et al., 1986b) , we evaluated both uptake and retention of AD 198 in sensitive and progressively DOX-resistant L1210 mouse leukaemia cells. In a preliminary study, total anthracycline cellular accumulation was determined spectrophotometrically after 1 and 3 h of continuous exposure to AD 198 at three different concentrations (Table I) . From results outlined in Table I , it is evident that drug accumulation is dependent on extracellular concentration but independent of time of exposure (1 h vs 3 h). Further, unlike results with DOX where differences were seen , accumulation of AD 198 was comparable in the sensitive and resistant sublines. In another study, HPLC analytical data were used to determine intracellular anthracycline content after 3 h exposure to the ICo concentrations of AD 198. Data provided in Table II additionally document the extent of drug uptake by cells exposed to AD 198. In this, as in related studies (Israel et al., 1987b , AD 198 was found to accumulate rapidly and extensively in cells, achieving a cell:medium partition ratio of 7:3.
The putative role of P-glycoprotein, which is overexpressed 'Numbers in parenthesis, for the retention studies, represent the per cent of total anthracycline retained in the cells at the indicated times relative to the amount present after the 3-h accumulation phase.
in the DOX-resistant L1210 cells (Ganapathi et al., 1989) , is suggested to involve active drug efflux (Gerlach et al., 1986b Cytotoxic effects in vitro of AD288 following treatment for 3 h in sensitive and progressively DOX-resistant L1210 mouse leukaemia cells are outlined in Figure 3 . In contrast to AD 198, cross-resistance to AD 288 was observed (IC50 of AD 288 in L1210/S, L1210/DOX0.05 and L1210/DOX0.25 cells, 0.25, 0.5, and 1.0 jig ml-', respectively).
To determine if in vitro results have validity in an in vivo setting, the antitumour efficacy of AD 198 compared to DOX was evaluated in mice implanted with the sensitive and progressively DOX-resistant tumours. Results of studies with sensitive and progressively DOX-resistant L1210 mouse leukaemia are outlined in Figure 4 . In the L1210/S line, DOX was effective, and survival was more than doubled (104% ILS) compared to the untreated control; approximately 10% long-term survivors (>60 days) were observed in replicate experiments. As previously noted with this tumour , AD 198 was more effective than DOX; in these studies a % ILS of 189 was obtained, Similar studies comparing the therapeutic efficacy of DOX and AD 198 in sensitive and DOX-resistant B16-BL6 cells are shown in Figure 5 . Therapeutic efficacy of DOX in the B16-BL6/S cells was apparent (55% ILS). However, in contrast to the results with L1210/S (Figure 4) , AD 198 was found to be only equiactive with DOX in the B16-BL6/S model (61% ILS and no long-term survivors). Similar to results with the DOX-resistant L1210 sublines, DOX was ineffective against the B16-BL6/DOXO.05 and B16-BL6/ DOXO.25 tumour systems in vivo. In contrast to the results with the DOX-resistant-L1210 cells, AD 198 retained effectiveness (76% ILS) in the B16-BL6/DOXO.05 model at a level essentially equivalent to that in the parent sensitive B16-BL6/S system. However, with the B16/BL6/DOXO.25 cells, no therapeutic efficacy of AD 198 was present.
Discussion
Tumour cell resistance and, in particular, the multidrug resistant phenotype have received considerable attention at the experimental and clinical level (Gerlach et al., 1986b) . Since the identification of P-glycoprotein in MDR cells, and its homology to bacterial active transport proteins, resistance to drugs with diverse mechanisms of action has been attributed to an active drug efflux process (Gerlach et al., 1986a) . Although this mechanism has gained considerable popularity, at least with anthracyclines, there is actually limited correlation between alteration in drug uptake/efflux and expression of resistance (Ganapathi et al., 1986; Louie et al., 1986; . The present investigation was undertaken to explore the relationship between cytotoxicity and drug accumulation/retention with a novel lipophilic DOX analogue, which in other in vitro studies (Maniar et al., 1988; Sweatman et al., 1988) has demonstrated an ability to circumvent resistance in MDR cells.
Using two sets of parent sensitive and progressively DOXresistant murine cell lines, the present study shows that, in (Tables I and II) . This is in marked contrast to DOX which, in other studies, accumulates gradually and, at equilibrium, achieves a cell:media partitioning ratio of only 1:11 following cellular drug exposure B16-BL6/S (parent-sensitive) (Traganos et al., 1985; Israel et al., 1987b Israel et al., , 1989 (Table II) . Also, no significant differences in cellular drug biotransformation were seen in L1210/S vs progressively DOX-resistant cells (Table II) .
Like many other MDR model systems (Gerlach et al., 1986b), the DOX-resistant sublines of L1210 leukaemia (Ganapathi et al., 1989) and B16-BL6 melanoma (Ganapathi et al., 1987) (Ganapathi et al., 1989) . Although AD 198 and its principal biotransformation product AD 288 cause significant levels of protein-associated DNA strand breaks on alkaline elution assay (Potmesil et al., 1986) (Tsuruo et al., 1982; Ganapathi & Grabowski, 1983) . However, in studies with the calmodulin inhibitor trifluoperazine (TFP), this agent was previously shown to be ineffective in modulating cellular drug levels and/or cytotoxicity of lipophilic anthracyclines (Ganapathi et al., 1984 (Ganapathi et al., , 1985 . Similarly, in the present study, neither the accumulation nor the cytotoxicity of AD 198 were altered by TFP in the sensitive or DOX-resistant sublines.
These results with TFP are distinct from those observed with DOX in > 100 fold DOX-resistant tumour cells (Ganapathi et al., 1984 (Ganapathi et al., , 1985 . Consistent with earlier in vivo observations (Israel et al., 1987a; Israel & Seshadri, 1986) Figure 3 vs Figure 1) , when administered to tumour-bearing animals this agent is effective at a level only equivalent to that of DOX (Israel et al., 1987a) . Biochemically, AD 288 behaves more like DOX than like AD 198 in its interactions with DNA and it fails to show the membrane-active properites seen with AD 198 (Israel et al., 1987a) . In the present study, against L1210/DOXO.05 and L1210/DOXO.25 cells, the ICm in vitro of AD 288 was 2-and 4-fold greater, respectively, than against L1210/S cells (Figure 3) , and this may explain the absence of antitumour activity in vivo against the DOXresistant L1210 sublines.
Studies with the highly disseminated L1210/S and progressively DOX-resistant L1210 sublines point to the need to evaluate solid tumour models in vivo to demonstrate potential circumvention of resistance by drugs, and in this regard, antitumour activity in vivo of AD 198 with the B16-BL6/S melanoma and its progressively DOX-resistant sublines becomes more informative. AD 198 and DOX are equally effective against B16-BL6/S in vivo ( Figure 5) ; the lesser response of these drugs against this tumour compared to L1210/S suggests possible differences in the intrinsic sensitivity of the tumour cells to these agents. However, with the B16-BL6 model system, the activity of AD 198 is retained against the 10-fold DOX-resistant tumour, while DOX is ineffective. Thus, the sensitivity of AD 198 vs B16-BL6/ DOX0.05 seen in vitro is correspondingly achieved in vivo. In the 40-fold DOX-resistant subline in vivo with AD 198 activity is abolished. Since only a 2-fold level of resistance is seen in vitro with AD 198 in the B16-BL6/DOX0.25 (40-fold DOX-resistant) compared to parent B16-BL6/S cells, loss of in vivo activity suggests, at least for this system, that a 2-fold difference of IC_0 in vitro may be capable of negating the therapeutic activity of an otherwise superior DOX analogue.
In summary, results from this study demonstratre that in progressively DOX-resistant (<40-fold) model systems, little (<2-fold) or no cross-resistance in vitro to AD 198 is observed. Although, unlike DOX , the cellular uptake and/or retention of AD 198 is not dependent on the level of resistance, for equivalent cytotoxicity the 40-fold resistant tumours tend to accumulate and retain significantly higher levels of drug. Finally, the limited therapeutic efficacy of AD 198 against DOX-resistant tumours suggests that in vitro cellular pharmacokinetics and cytotoxicity studies of novel anthracyclines by themselves may be of limited value in characterising therapeutic efficacy of these agents for the treatment of DOX-resistant tumours in vivo. However, the results presented provide an excellent model for further studies to identify the factors in MDR cells which result in resistance to chemotherapy in vitro and in vivo.
